Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis.

IF 0.5 Q4 ONCOLOGY International Cancer Conference Journal Pub Date : 2023-05-12 eCollection Date: 2023-10-01 DOI:10.1007/s13691-023-00611-z

Yusuke Seyama, Takeshi Yamada, Hirosumi Suzuki, Satoshi Fukuda, Miki Tsuji, Yusuke Niisato, Suguru Hirose, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Ichinosuke Hyodo

{"title":"Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis.","authors":"Yusuke Seyama, Takeshi Yamada, Hirosumi Suzuki, Satoshi Fukuda, Miki Tsuji, Yusuke Niisato, Suguru Hirose, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Ichinosuke Hyodo","doi":"10.1007/s13691-023-00611-z","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric neuroendocrine carcinomas (NEC) are highly aggressive cancer with dismal prognosis. Platinum-based chemotherapy is used as the first-line treatment for this entity. However, there are no established therapeutic guidelines for platinum-resistant gastric NEC. We herein report a patient with metastatic gastric NEC who achieved durable and complete response to nivolumab with radiotherapy for oligoprogressive metastasis. A 70-year-old male patient had recurrences of resected gastric NEC, involving the liver and lymph nodes. His disease became refractory to cisplatin and etoposide combination therapy, after which he was treated with nivolumab. All the tumors showed marked shrinkage. However, 1 year after starting nivolumab, one metastatic lesion of the liver began to enlarge, and radiotherapy was performed to the lesion. Thereafter, a complete response was obtained, which has been maintained without any treatment for the past 2 years.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"268-273"},"PeriodicalIF":0.5000,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421835/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-023-00611-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastric neuroendocrine carcinomas (NEC) are highly aggressive cancer with dismal prognosis. Platinum-based chemotherapy is used as the first-line treatment for this entity. However, there are no established therapeutic guidelines for platinum-resistant gastric NEC. We herein report a patient with metastatic gastric NEC who achieved durable and complete response to nivolumab with radiotherapy for oligoprogressive metastasis. A 70-year-old male patient had recurrences of resected gastric NEC, involving the liver and lymph nodes. His disease became refractory to cisplatin and etoposide combination therapy, after which he was treated with nivolumab. All the tumors showed marked shrinkage. However, 1 year after starting nivolumab, one metastatic lesion of the liver began to enlarge, and radiotherapy was performed to the lesion. Thereafter, a complete response was obtained, which has been maintained without any treatment for the past 2 years.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胃神经内分泌癌通过nivolumab治疗多发转移和放疗治疗少进展转移表现出完全持久的反应。

胃神经内分泌癌（NEC）是侵袭性很强的癌症，预后极差。以铂为基础的化疗被用作该实体的一线治疗。然而，目前还没有针对铂耐药性胃NEC的既定治疗指南。我们在此报告了一名患有转移性胃NEC的患者，他对nivolumab通过放射治疗寡进行性转移获得了持久和完全的反应。一位70岁的男性患者，切除的胃NEC复发，涉及肝脏和淋巴结。他的疾病对顺铂和依托泊苷联合治疗变得难治，之后他接受了尼沃单抗治疗。所有肿瘤均有明显缩小。然而，在开始nivolumab治疗1年后，一个肝脏转移性病变开始扩大，并对该病变进行了放射治疗。此后，获得了完全的应答，该应答在过去2年中一直保持不变，没有任何治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)